NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Not exactly sure how these cohorts are cutoff? What time period does each one really represent? However, if you believe progressive patients also made up part of the first 38 enrolled, and were not subject to exclusion, that would easily explain the 38 poorer performance as well.

I suspect progressed patients would not be allowed in before May 2012, because they would no longer fall under the diagnosis of "newly" diagnosed, but rather "recurrent." Obviously they were actively excluded after May 2012. Maybe just better drafting.

So would not diagnosing MGMT status -- could have been an imbalance.

If six to eight survived nonetheless out of 38 enrolled to 36 months and they had two strikes against the group, it's fairly remarkable. Still good showing.

Then that would explain better OS after the first 38 as well. The efficacy would be in choosing a more typical patient selection thereafter. -- even though they hamstrung themselves by removing some psPD.

Nothing publicly provided by the company explains the intraimprovement for the 293 patient group from beginning to end that I'm aware of, except perhaps which clinics were enrolling when. Seemed to be a dip in OS results when a youth clinic was reaching certain timelines. Could have been proneural.

Fraunhofer seems to like the thought they optimized manufacturing during the second half of the trial. That might account for the eventual increase in three year survival.